Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carci...
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses phase III findings from the IPATential150 trial, which showed the effectiveness of ipatasertib plus abir...
Sumanta K. Pal, MD, of City of Hope, discusses phase II results from the SWOG 1500 study, which showed that compared with crizotinib and savolitinib, cabozantinib was the onl...
Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to de...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuses a preliminary phase II analysis of the HIF-2a inhibitor belzutifan in combination with cabozantinib, which sho...
